Compare GSK plc (GSK) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs PAGSEG Inc — how do they compare? GSK plc trades at $52.66 (market cap $101.34B), while PAGSEG Inc trades at $9.21 (market cap $2.57B). The key difference: GSK plc is far larger — about 39.4× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (11.29%). Which is the better fit depends on your goals.
| GSK | PAGS | |
|---|---|---|
Market Cap | $101.34B | $2.57B |
Sector | Health | Technology |
52-Week High | $61.18 | $12.00 |
52-Week Low | $36.20 | $7.75 |
Enterprise Value | $121.95B | $10.21B |
Dividend Yield | 3.49% | 11.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
PAGS trades at $9.205, down 0.81% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported 2025 revenue of $20.41B and net income of $2.12B, with strong profitability margins and attractive valuation ratios, including a P/E of 6.52. Recent news highlights PagSeguro's potential benefit from Brazil's rate-cutting cycle and its deep valuation discount.
The outlook for PAGS is positive, driven by robust fundamentals, a favorable analyst consensus, and potential tailwinds from monetary policy. Key risks include macroeconomic pressures in Brazil and competitive threats in the financial services sector. The stock presents a value opportunity with upside potential, contingent on execution and economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
